Today on Drug Discovery & Development
Data breaches targeting pharma companies are ‘rampant,’ report says
For pharmaceutical companies, cyberattacks can get expensive quickly. In 2021, the average cost of a data breach was $5 million, which is the third-highest of any industry, according to the IBM Cost of a Data Breach report. Cyberattacks can also cause operational disruptions. For example, in 2017, Merck & Co. (NYSE: MRK) struggled to keep…
What’s really happening with clinical trial innovation?
The clinical trial landscape has evolved significantly in the past two years. But given the quick embrace of decentralized clinical trials and growing traction of apps, digital health and other technologies in the space, it can be difficult to separate hype from reality. To learn more about the evolving landscape, we caught up with Libbi…
Drug Discovery and Development See More >
Data breaches targeting pharma companies are ‘rampant,’ report says
For pharmaceutical companies, cyberattacks can get expensive quickly. In 2021, the average cost of a data breach was $5 million, which is the third-highest of any industry, according to the IBM Cost of a Data Breach report. Cyberattacks can also cause operational disruptions. For example, in 2017, Merck & Co. (NYSE: MRK) struggled to keep…
Sponsored Content See More >
These are not fireworks: The objective truthBy Jan Barghaan, Strategic Marketing Manager Life Science, Olympus Europa No, not fireworks — it’s actually a single colony of…
AI technology automates tedious cell culture work and analysesBy Joanna Hawryluk, PhD, Product Manager, Olympus Life Science Since the early 20th century, cell culture has been considered the…
What is Human AB Serum?By Trevor Smith, MS MBA, Product Manager, Immune Cells Human AB Serum is a staple in the biological research field,…
Resolving binding kinetics on a microplate readerWith a better understanding of the causes and mechanisms behind diseases arises a need for new treatment options and drugs…
Noble expands its services for its clients into Human FactorsHuman Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug…
Micro 3D Printing Advances Biomarker DetectionResearchers in China have used Projection Micro Stereolithography (PµSL) to improve the fabrication of micropillar array electrodes (µAEs) for the…
Genomics/Proteomics See More >
DNA Script raises $165M Series C for DNA printing platform
DNA Script announced today that it raised $165 million in a Series C financing round, bringing its total capital raised to $280 million. South San Francisco-based DNA Script earmarked the funds raised to accelerate expansion and commercialization for the company’s Syntax benchtop nucleic acid printer and to broaden its portfolio of products powered by enzymatic…
Infectious Disease See More >
Moderna commences Phase 2 study of omicron-specific booster
Mere days after rivals Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) announced the launch of a study testing an omicron-based booster vaccine candidate, Moderna (NSDQ:MRNA) has announced its own trial of an omicron-specific vaccine. The vaccine booster candidate, mRNA-1273.529, will be the subject of a Phase 2 study involving approximately 600 participants divided into two cohorts. The…
Leyden Labs closes $140M in Series B funding
Pfizer and BioNTech test omicron-specific COVID-19 vaccine in adults
FDA extends approval of remdesivir to encompass non-hospitalized high-risk
Valneva shares surge 30% after announcing its vaccine candidate neutralized omicron in neutralizing antibody study
Oncology See More >
Zymeworks to cut headcount at least 25% by end of 2022
Soon after taking the reins of Zymeworks (NYSE:ZYME), new Chair and CEO Kenneth Galbraith has decided to sharpen the company’s focus and reduce the firm’s headcount. To free up cash, the company plans to lay off at least one-quarter of its staff, including 10 members (50%) of its senior management team. The Vancouver–headquartered company also intends to…
Brazilian regulators authorize Sorrento Phase 2 clinical trial of COVI-MSC in COVID-19 long-haulers
FDA grants Enhertu priority review for HER2-positive positive metastatic breast cancer
NeuroMetrix’s Quell wins FDA breakthrough designation to treat certain chemo side effects
